


Isovitexin

Cat. No.:	HY-N0773		
CAS No.:	38953-85-4		
Molecular Formula:	C ₂₁ H ₂₀ O ₁₀		
Molecular Weight:	432.38		
Target:	JNK; NF-κB		
Pathway:	MAPK/ERK Pathway; NF-κB		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (57.82 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
Preparing Stock Solutions	1 mM	2.3128 mL	11.5639 mL	23.1278 mL
	5 mM	0.4626 mL	2.3128 mL	4.6256 mL
	10 mM	0.2313 mL	1.1564 mL	2.3128 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.81 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.81 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.81 mM); Clear solution 			

BIOLOGICAL ACTIVITY

Description	Isovitexin is a flavonoid isolated from passion flower, Cannabis and, and the palm, possesses anti-inflammatory and anti-oxidant activities; Isovitexin acts like a JNK1/2 inhibitor and inhibits the activation of NF-κB.		
IC₅₀ & Target	JNK1	JNK2	NF-κB
In Vitro	Isovitexin protects against LPS-induced oxidative damage by suppressing intracellular ROS generation, and also attenuates the effect of H ₂ O ₂ on cell viability. Isovitexin (0-100 μg/mL) with LPS (2 μg/mL) is not cytotoxic to RAW 264.7 cells, but 200 μ		

g/mL Isoviteixin shows significant cytotoxicity. Isoviteixin (25, 50 µg/mL) inhibits LPS-induced increases in TNF-α, IL-6, iNOS, and COX-2 levels. Isoviteixin (25, 50 µg/mL) also suppresses the IκBα phosphorylation and degradation in RAW 264.7 cells, and such an effect is consistent with that of JNK1/2 inhibitor^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Isoviteixin (50 and 100 mg/kg, i.p.) causes less severe histopathological changes in the lung sections, and reduces inflammatory cell count in LPS-induced mice. Isoviteixin (50 and 100 mg/kg, i.p.) protects against LPS-induced inflammation and oxidative stress in LPS-induced ALI mice by decreasing TNF-α and IL-6 production, ROS generation, and MPO and MDA content, increasing SOD and GSH levels and effectively inhibiting the protein expression of iNOS and COX-2^[1]. Isoviteixin (25, 50, 100 mg/kg) dose-dependently reduces the survival rate of LPS/D-gal induced hepatic injury in mice. Isoviteixin also inhibits NF-κB activation and up-regulates Nrf2 and HO-1 induced by LPS/D-gal in mice^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[1]

Cell viability is determined by an MTT assay. RAW 264.7 cells are plated in 96-well plates (1×10^4 cells/well) and incubated with various concentrations of Isoviteixin (final concentration: 0-200 µg/mL) and LPS (2 µg/mL) for 24 h. In addition, the cells are pretreated with IV (25 or 50 µg/mL) for 1 h, followed by the addition of H₂O₂ (300 µM). After 24 h, MTT (5 mg/mL) is added to the cells, which are then incubated for another 4 h^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^[1]

Mice^[1]

To create an ALI model, mice are randomly divided into six groups: control (saline), Isoviteixin only (100 mg/kg, dissolved in 0.5% DMSO), LPS only (0.5 mg/kg, dissolved in saline), LPS (0.5 mg/kg) + Isoviteixin (50 or 100 mg/kg), and LPS (0.5 mg/kg) + dexamethasone (Dex, 5 mg/kg dissolved in saline). Isoviteixin or Dex (5 mg/kg) are administered Isoviteixin. After exposure to Isoviteixin or Dex for 1 h, the mice are anesthetized with diethyl ether, and LPS is administered intranasally (i.n.) to induce lung injury. After LPS administration for 12 h, the animals are euthanized. Accordingly, bronchoalveolar lavage fluid (BALF) and lung tissue samples are harvested to measure cytokine levels; ROS generation; SOD, GSH, MDA and MPO activity; and COX-2, iNOS, HO-1, and Nrf2 protein expression^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Acta Pharm Sin B. 2021 Jan;11(1):143-155.
- Food Chem. 16 December 2021, 131872.
- J Inflamm Res. 2021 Apr 13;14:1403-1414.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Lv H, et al. Isoviteixin Exerts Anti-Inflammatory and Anti-Oxidant Activities on Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting MAPK and NF-κB and Activating HO-1/Nrf2 Pathways. Int J Biol Sci. 2016 Jan 1;12(1):72-86.

[2]. Hu JJ, et al. Isoviteixin alleviates liver injury induced by lipopolysaccharide/d-galactosamine by activating Nrf2 and inhibiting NF-κB activation. Microb Pathog. 2018 Mar 29;119:86-92.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA